Cargando…

BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures

Idiopathic pulmonary fibrosis (IPF) is a form of chronic and irreversible fibrosing interstitial pneumonia of unknown etiology. Although antifibrotic treatments have shown a reduction of lung function decline and a slow disease progression, IPF is characterize by a very high mortality. Emerging evid...

Descripción completa

Detalles Bibliográficos
Autores principales: Vantaggiato, Lorenza, Shaba, Enxhi, Cameli, Paolo, Bergantini, Laura, d’Alessandro, Miriana, Carleo, Alfonso, Montuori, Giusy, Bini, Luca, Bargagli, Elena, Landi, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861565/
https://www.ncbi.nlm.nih.gov/pubmed/36674438
http://dx.doi.org/10.3390/ijms24020925
_version_ 1784874873108037632
author Vantaggiato, Lorenza
Shaba, Enxhi
Cameli, Paolo
Bergantini, Laura
d’Alessandro, Miriana
Carleo, Alfonso
Montuori, Giusy
Bini, Luca
Bargagli, Elena
Landi, Claudia
author_facet Vantaggiato, Lorenza
Shaba, Enxhi
Cameli, Paolo
Bergantini, Laura
d’Alessandro, Miriana
Carleo, Alfonso
Montuori, Giusy
Bini, Luca
Bargagli, Elena
Landi, Claudia
author_sort Vantaggiato, Lorenza
collection PubMed
description Idiopathic pulmonary fibrosis (IPF) is a form of chronic and irreversible fibrosing interstitial pneumonia of unknown etiology. Although antifibrotic treatments have shown a reduction of lung function decline and a slow disease progression, IPF is characterize by a very high mortality. Emerging evidence suggests that IPF increases the risk of lung carcinogenesis. Both diseases show similarities in terms of risk factors, such as history of smoking, concomitant emphysema, and viral infections, besides sharing similar pathogenic pathways. Lung cancer (LC) diagnosis is often difficult in IPF patients because of the diffuse lung injuries and abnormalities due to the underlying fibrosis. This is reflected in the lack of optimal therapeutic strategies for patients with both diseases. For this purpose, we performed a proteomic study on bronchoalveolar lavage fluid (BALF) samples from IPF, LC associated with IPF (LC-IPF) patients, and healthy controls (CTRL). Molecular pathways involved in inflammation, immune response, lipid metabolism, and cell adhesion were found for the dysregulated proteins in LC-IPF, such as TTHY, APOA1, S10A9, RET4, GDIR1, and PROF1. The correlation test revealed a relationship between inflammation- and lipid metabolism-related proteins. PROF1 and S10A9, related to inflammation, were up-regulated in LC-IPF BAL and serum, while APOA1 and APOE linked to lipid metabolism, were highly abundant in IPF BAL and low abundant in IPF serum. Given the properties of cytokine/adipokine of the nicotinamide phosphoribosyltransferase, we also evaluated its serum abundance, highlighting its down-regulation in LC-IPF. Our retrospective analyses of BAL samples extrapolated some potential biomarkers of LC-IPF useful to improve the management of these contemporary pathologies. Their differential abundance in serum samples permits the measurement of these potential biomarkers with a less invasive procedure.
format Online
Article
Text
id pubmed-9861565
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98615652023-01-22 BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures Vantaggiato, Lorenza Shaba, Enxhi Cameli, Paolo Bergantini, Laura d’Alessandro, Miriana Carleo, Alfonso Montuori, Giusy Bini, Luca Bargagli, Elena Landi, Claudia Int J Mol Sci Article Idiopathic pulmonary fibrosis (IPF) is a form of chronic and irreversible fibrosing interstitial pneumonia of unknown etiology. Although antifibrotic treatments have shown a reduction of lung function decline and a slow disease progression, IPF is characterize by a very high mortality. Emerging evidence suggests that IPF increases the risk of lung carcinogenesis. Both diseases show similarities in terms of risk factors, such as history of smoking, concomitant emphysema, and viral infections, besides sharing similar pathogenic pathways. Lung cancer (LC) diagnosis is often difficult in IPF patients because of the diffuse lung injuries and abnormalities due to the underlying fibrosis. This is reflected in the lack of optimal therapeutic strategies for patients with both diseases. For this purpose, we performed a proteomic study on bronchoalveolar lavage fluid (BALF) samples from IPF, LC associated with IPF (LC-IPF) patients, and healthy controls (CTRL). Molecular pathways involved in inflammation, immune response, lipid metabolism, and cell adhesion were found for the dysregulated proteins in LC-IPF, such as TTHY, APOA1, S10A9, RET4, GDIR1, and PROF1. The correlation test revealed a relationship between inflammation- and lipid metabolism-related proteins. PROF1 and S10A9, related to inflammation, were up-regulated in LC-IPF BAL and serum, while APOA1 and APOE linked to lipid metabolism, were highly abundant in IPF BAL and low abundant in IPF serum. Given the properties of cytokine/adipokine of the nicotinamide phosphoribosyltransferase, we also evaluated its serum abundance, highlighting its down-regulation in LC-IPF. Our retrospective analyses of BAL samples extrapolated some potential biomarkers of LC-IPF useful to improve the management of these contemporary pathologies. Their differential abundance in serum samples permits the measurement of these potential biomarkers with a less invasive procedure. MDPI 2023-01-04 /pmc/articles/PMC9861565/ /pubmed/36674438 http://dx.doi.org/10.3390/ijms24020925 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Vantaggiato, Lorenza
Shaba, Enxhi
Cameli, Paolo
Bergantini, Laura
d’Alessandro, Miriana
Carleo, Alfonso
Montuori, Giusy
Bini, Luca
Bargagli, Elena
Landi, Claudia
BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures
title BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures
title_full BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures
title_fullStr BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures
title_full_unstemmed BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures
title_short BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures
title_sort bal proteomic signature of lung adenocarcinoma in ipf patients and its transposition in serum samples for less invasive diagnostic procedures
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861565/
https://www.ncbi.nlm.nih.gov/pubmed/36674438
http://dx.doi.org/10.3390/ijms24020925
work_keys_str_mv AT vantaggiatolorenza balproteomicsignatureoflungadenocarcinomainipfpatientsanditstranspositioninserumsamplesforlessinvasivediagnosticprocedures
AT shabaenxhi balproteomicsignatureoflungadenocarcinomainipfpatientsanditstranspositioninserumsamplesforlessinvasivediagnosticprocedures
AT camelipaolo balproteomicsignatureoflungadenocarcinomainipfpatientsanditstranspositioninserumsamplesforlessinvasivediagnosticprocedures
AT bergantinilaura balproteomicsignatureoflungadenocarcinomainipfpatientsanditstranspositioninserumsamplesforlessinvasivediagnosticprocedures
AT dalessandromiriana balproteomicsignatureoflungadenocarcinomainipfpatientsanditstranspositioninserumsamplesforlessinvasivediagnosticprocedures
AT carleoalfonso balproteomicsignatureoflungadenocarcinomainipfpatientsanditstranspositioninserumsamplesforlessinvasivediagnosticprocedures
AT montuorigiusy balproteomicsignatureoflungadenocarcinomainipfpatientsanditstranspositioninserumsamplesforlessinvasivediagnosticprocedures
AT biniluca balproteomicsignatureoflungadenocarcinomainipfpatientsanditstranspositioninserumsamplesforlessinvasivediagnosticprocedures
AT bargaglielena balproteomicsignatureoflungadenocarcinomainipfpatientsanditstranspositioninserumsamplesforlessinvasivediagnosticprocedures
AT landiclaudia balproteomicsignatureoflungadenocarcinomainipfpatientsanditstranspositioninserumsamplesforlessinvasivediagnosticprocedures